X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement will bring to GC Biopharma 3 programs, including MarzAA (marzeptacog alfa), an engineered factor VIIa which is ready for Phase 3 clinical stage development.
Lead Product(s): Marzeptacog Alfa
Therapeutic Area: Genetic Disease Product Name: MarzAA
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GC Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 27, 2023
Details:
F351 is a next-generation pirfenidone analog in Phase 3 clinical development for the treatment of HBV associated liver fibrosis in China and the combined company expects to file an IND in the US and commence Phase 2 studies in 2023.
Lead Product(s): Hydronidone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: GNI Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 27, 2022
Details:
Companies have signed agreement under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG.
Lead Product(s): CB 2782-PEG
Therapeutic Area: Ophthalmology Product Name: CB 2782-PEG
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $60.0 million Upfront Cash: $60.0 million
Deal Type: Agreement May 23, 2022
Details:
Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.
Lead Product(s): CB 2782-PEG
Therapeutic Area: Ophthalmology Product Name: CB 2782-PEG
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
Details:
Marzeptacog alfa (activated), or MarzAA demonstrates its potential in treating multiple rare bleeding disorders. MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding.
Lead Product(s): Marzeptacog Alfa
Therapeutic Area: Rare Diseases and Disorders Product Name: MarzAA
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The objective of the study was to conduct simulations using a MarzAA-specific, population pharmacokinetic (PK) model in a large population following different dose levels of MarzAA.
Lead Product(s): Marzeptacog Alfa
Therapeutic Area: Genetic Disease Product Name: MarzAA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
The natural history of disease study will follow up and assess these patients for clinical outcomes, biomarkers of complement dysregulation as well as safety and effectiveness of their current treatments in preparation for the clinical development program of CB 4332.
Lead Product(s): CB 4332
Therapeutic Area: Immunology Product Name: CB 4332
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
This trial is being conducted in parallel with the ongoing Phase 3 registration trial evaluating MarzAA for the treatment of episodic bleeds in patients with Hemophilia A or B with inhibitors.
Lead Product(s): Marzeptacog Alfa
Therapeutic Area: Genetic Disease Product Name: MarzAA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
The patent protects nucleic acids encoding modified proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, Catalyst's potential best-in-class treatment for dry AMD, currently licensed to Biogen.
Lead Product(s): CB 2782-PEG
Therapeutic Area: Ophthalmology Product Name: CB 2782-PEG
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
The Phase 3 study a cross-over study to evaluate the efficacy and safety of MarzAA for on-demand treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia A or B with inhibitors, compared to Standard of Care.
Lead Product(s): Marzeptacog alfa
Therapeutic Area: Genetic Disease Product Name: MarzAA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
